Nanobiotix Overview
Valuation check: NBTX's ROE is 96.06%, above the Healthcare sector average of 22.76%.
Get informed when a big investor buys or sells
+ Follow96.06%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Nanobiotix (NBTX) currently reports a ROE of 96.06%. That is above the Healthcare sector average of 22.76%. Use the charts on this page to explore Nanobiotix's ROE history and peer comparisons.
Nanobiotix's ROE of 96.06% is higher than the Healthcare sector average of 22.76%. That is roughly 322.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Nanobiotix's current 96.06% should be judged against Healthcare norms (sector average: 22.76%) and against NBTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 96.06%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Nanobiotix, and consider following NBTX for alerts when major investors trade the stock.
Nanobiotix is classified in the Healthcare sector. On ROE, it currently shows 96.06% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NBTX with unrelated industries.
